BIOMAT Database Logo BIOMAT Database Logo

Feasibility of Water Therapy for Slowing Autosomal Dominant Polycystic Kidney Disease Progression. 2024

Hreedi Dev, and Chenglin Zhu, and Irina Barash, and Jon D Blumenfeld, and Xinzi He, and Arindam RoyChoudhury, and Alan Wu, and Martin R Prince
Department of Radiology, Weill Cornell Medicine, New York, New York.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D005260 Female Females
D005440 Fluid Therapy Therapy whose basic objective is to restore the volume and composition of the body fluids to normal with respect to WATER-ELECTROLYTE BALANCE. Fluids may be administered intravenously, orally, by intermittent gavage, or by HYPODERMOCLYSIS. Oral Rehydration Therapy,Rehydration,Rehydration, Oral,Oral Rehydration,Rehydration Therapy, Oral,Therapy, Fluid,Therapy, Oral Rehydration,Fluid Therapies,Oral Rehydration Therapies,Oral Rehydrations,Rehydration Therapies, Oral,Rehydrations,Rehydrations, Oral,Therapies, Fluid,Therapies, Oral Rehydration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016891 Polycystic Kidney, Autosomal Dominant Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function. Autosomal Dominant Polycystic Kidney,Kidney, Polycystic, Autosomal Dominant,ADPKD,Adult Polycystic Kidney Disease,Adult Polycystic Kidney Disease Type 1,Adult Polycystic Kidney Disease Type 2,Polycystic Kidney Disease 2,Polycystic Kidney Disease, Adult,Polycystic Kidney Disease, Adult Type 2,Polycystic Kidney Disease, Adult, Type II,Polycystic Kidney Disease, Autosomal Dominant,Polycystic Kidney Disease, Type 2,Polycystic Kidney, Type 1 Autosomal Dominant Disease,Polycystic Kidney, Type 2 Autosomal Dominant Disease
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Hreedi Dev, and Chenglin Zhu, and Irina Barash, and Jon D Blumenfeld, and Xinzi He, and Arindam RoyChoudhury, and Alan Wu, and Martin R Prince
Decade in review--polycystic kidney disease: Slowing progression of autosomal dominant polycystic kidney disease.
November 2015, Nature reviews. Nephrology,
Hreedi Dev, and Chenglin Zhu, and Irina Barash, and Jon D Blumenfeld, and Xinzi He, and Arindam RoyChoudhury, and Alan Wu, and Martin R Prince
Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease.
April 2017, Giornale de techniche nefrologiche & dialitiche,
Hreedi Dev, and Chenglin Zhu, and Irina Barash, and Jon D Blumenfeld, and Xinzi He, and Arindam RoyChoudhury, and Alan Wu, and Martin R Prince
Predictors of autosomal dominant polycystic kidney disease progression.
November 2014, Journal of the American Society of Nephrology : JASN,
Hreedi Dev, and Chenglin Zhu, and Irina Barash, and Jon D Blumenfeld, and Xinzi He, and Arindam RoyChoudhury, and Alan Wu, and Martin R Prince
Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.
April 2022, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Hreedi Dev, and Chenglin Zhu, and Irina Barash, and Jon D Blumenfeld, and Xinzi He, and Arindam RoyChoudhury, and Alan Wu, and Martin R Prince
Autosomal dominant polycystic kidney disease: modification of disease progression.
October 2001, Lancet (London, England),
Hreedi Dev, and Chenglin Zhu, and Irina Barash, and Jon D Blumenfeld, and Xinzi He, and Arindam RoyChoudhury, and Alan Wu, and Martin R Prince
Genetics and Autosomal Dominant Polycystic Kidney Disease Progression.
January 2017, Contributions to nephrology,
Hreedi Dev, and Chenglin Zhu, and Irina Barash, and Jon D Blumenfeld, and Xinzi He, and Arindam RoyChoudhury, and Alan Wu, and Martin R Prince
Nutraceutical for Autosomal Dominant Polycystic Kidney Disease Therapy.
January 2016, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Hreedi Dev, and Chenglin Zhu, and Irina Barash, and Jon D Blumenfeld, and Xinzi He, and Arindam RoyChoudhury, and Alan Wu, and Martin R Prince
Renal disease progression in autosomal dominant polycystic kidney disease.
August 2012, Clinical and experimental nephrology,
Hreedi Dev, and Chenglin Zhu, and Irina Barash, and Jon D Blumenfeld, and Xinzi He, and Arindam RoyChoudhury, and Alan Wu, and Martin R Prince
Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?
September 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Hreedi Dev, and Chenglin Zhu, and Irina Barash, and Jon D Blumenfeld, and Xinzi He, and Arindam RoyChoudhury, and Alan Wu, and Martin R Prince
Mechanisms of progression in autosomal dominant polycystic kidney disease.
December 1997, Kidney international. Supplement,
Copied contents to your clipboard!